Ken Griffin Scynexis Inc Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Scynexis Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 10,300 shares of SCYX stock, worth $12,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,300
Previous 15,900
35.22%
Holding current value
$12,360
Previous $31,000
51.61%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SCYX
# of Institutions
48Shares Held
13.7MCall Options Held
21.9KPut Options Held
2.6K-
Federated Hermes, Inc. Pittsburgh, PA3.6MShares$4.31 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$2.68 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$2.02 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.45MShares$1.74 Million0.13% of portfolio
-
Amh Equity LTD600KShares$720,0001.24% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $39.2M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...